AR076400A1 - Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente - Google Patents
Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipienteInfo
- Publication number
- AR076400A1 AR076400A1 ARP100101364A ARP100101364A AR076400A1 AR 076400 A1 AR076400 A1 AR 076400A1 AR P100101364 A ARP100101364 A AR P100101364A AR P100101364 A ARP100101364 A AR P100101364A AR 076400 A1 AR076400 A1 AR 076400A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorder
- salt
- lactic acid
- phenyl
- piperazine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Lubricants (AREA)
Abstract
Reivindicacion 1: Una formulacion farmacéutica líquida que comprende una sal de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina seleccionada de la sal de adicion del ácido DL-láctico, la sal de adicion del ácido L-láctico y la sal de adicion del ácido D-láctico. Reivindicacion 6: Un método para el tratamiento de una enfermedad seleccionada de trastornos del estado de ánimo; trastorno depresivo grave; trastorno de ansiedad generalizada; trastorno de pánico; trastorno de estrés post-traumático; depresion asociada con el deterioro cognitivo, enfermedad de Alzheimer o ansiedad; depresion con síntomas residuales; dolor cronico; trastorno de la alimentacion o abuso, donde dicho método comprende la administracion de una cantidad terapéuticamente efectiva de una formulacion líquida de acuerdo con cualquiera de las reivindicaciones 1-5 a un paciente que lo necesita.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200900531 | 2009-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076400A1 true AR076400A1 (es) | 2011-06-08 |
Family
ID=42669509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101364A AR076400A1 (es) | 2009-04-24 | 2010-04-23 | Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente |
| ARP210101276A AR122051A2 (es) | 2009-04-24 | 2021-05-10 | Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101276A AR122051A2 (es) | 2009-04-24 | 2021-05-10 | Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US8940746B2 (es) |
| EP (1) | EP2421534B1 (es) |
| JP (1) | JP5722879B2 (es) |
| KR (1) | KR101779214B1 (es) |
| CN (2) | CN104693145A (es) |
| AR (2) | AR076400A1 (es) |
| AU (1) | AU2010238946B2 (es) |
| BR (1) | BRPI1015338C1 (es) |
| CA (1) | CA2759456C (es) |
| CL (1) | CL2011002631A1 (es) |
| CO (1) | CO6450649A2 (es) |
| CR (1) | CR20110554A (es) |
| DK (1) | DK2421534T3 (es) |
| DO (2) | DOP2011000319A (es) |
| EA (1) | EA021122B1 (es) |
| ES (1) | ES2512719T3 (es) |
| GE (1) | GEP20135938B (es) |
| HK (1) | HK1206732A1 (es) |
| HR (1) | HRP20140880T1 (es) |
| IL (1) | IL215362A0 (es) |
| MA (1) | MA33298B1 (es) |
| MX (1) | MX2011011119A (es) |
| MY (1) | MY155288A (es) |
| NZ (1) | NZ596431A (es) |
| PL (1) | PL2421534T3 (es) |
| PT (1) | PT2421534E (es) |
| RS (1) | RS53539B1 (es) |
| SG (1) | SG175124A1 (es) |
| SI (1) | SI2421534T1 (es) |
| SM (1) | SMT201400159B (es) |
| TN (1) | TN2011000504A1 (es) |
| TW (1) | TWI461224B (es) |
| UA (1) | UA106985C2 (es) |
| WO (1) | WO2010121621A1 (es) |
| ZA (1) | ZA201107731B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011011119A (es) | 2009-04-24 | 2011-11-04 | Lundbeck & Co As H | Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina. |
| CN104797566B (zh) * | 2012-09-19 | 2017-07-07 | 桑多斯股份公司 | 沃替西汀氢溴酸盐的新结晶形式 |
| EP3016937B1 (en) | 2013-07-01 | 2017-08-30 | LEK Pharmaceuticals d.d. | 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form |
| CN106103418A (zh) | 2014-01-31 | 2016-11-09 | 埃吉斯药物私人有限公司 | 沃替西汀盐的制备方法 |
| CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| GB201419261D0 (en) | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| WO2016125190A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof |
| JO3456B1 (ar) | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| DK3414216T3 (da) | 2016-02-08 | 2021-01-25 | Aaa Chemistry Aps | Arylering af alifatiske aminer |
| TW201806599A (zh) | 2016-07-01 | 2018-03-01 | Ｈ 朗德貝克公司 | 用於快速開始抗抑鬱作用之給藥方案 |
| CN106518807A (zh) * | 2016-09-17 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 乳酸沃替西汀晶型的制备方法 |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| CN107011289A (zh) * | 2017-03-10 | 2017-08-04 | 万全万特制药（厦门）有限公司 | 沃替西汀β晶型的制备方法 |
| GB2564887A (en) * | 2017-07-26 | 2019-01-30 | Azad Pharmaceutical Ingredients Ag | New route of synthesis to vortioxetine salts |
| WO2021198778A1 (en) | 2020-04-03 | 2021-10-07 | H. Lundbeck A/S | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| AU2004226838B8 (en) | 2003-04-04 | 2009-06-11 | H. Lundbeck A/S | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
| EA016054B1 (ru) * | 2006-06-16 | 2012-01-30 | Х. Лундбекк А/С | Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли |
| EP2044043B2 (en) * | 2006-06-16 | 2021-03-03 | H. Lundbeck A/S | 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物 |
| MX2011011119A (es) | 2009-04-24 | 2011-11-04 | Lundbeck & Co As H | Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina. |
-
2010
- 2010-04-16 MX MX2011011119A patent/MX2011011119A/es active IP Right Grant
- 2010-04-16 SI SI201030759T patent/SI2421534T1/sl unknown
- 2010-04-16 PT PT107141640T patent/PT2421534E/pt unknown
- 2010-04-16 CN CN201510093852.4A patent/CN104693145A/zh active Pending
- 2010-04-16 CN CN2010800171058A patent/CN102405048A/zh active Pending
- 2010-04-16 CA CA2759456A patent/CA2759456C/en active Active
- 2010-04-16 EA EA201171287A patent/EA021122B1/ru not_active IP Right Cessation
- 2010-04-16 TW TW099111946A patent/TWI461224B/zh active
- 2010-04-16 AU AU2010238946A patent/AU2010238946B2/en active Active
- 2010-04-16 MA MA34385A patent/MA33298B1/fr unknown
- 2010-04-16 ES ES10714164.0T patent/ES2512719T3/es active Active
- 2010-04-16 JP JP2012506342A patent/JP5722879B2/ja active Active
- 2010-04-16 BR BRPI1015338A patent/BRPI1015338C1/pt active IP Right Grant
- 2010-04-16 US US13/265,564 patent/US8940746B2/en active Active
- 2010-04-16 RS RSP20140505 patent/RS53539B1/en unknown
- 2010-04-16 MY MYPI2011004813A patent/MY155288A/en unknown
- 2010-04-16 SG SG2011073384A patent/SG175124A1/en unknown
- 2010-04-16 NZ NZ596431A patent/NZ596431A/xx unknown
- 2010-04-16 PL PL10714164T patent/PL2421534T3/pl unknown
- 2010-04-16 KR KR1020117025009A patent/KR101779214B1/ko active IP Right Grant
- 2010-04-16 UA UAA201113335A patent/UA106985C2/uk unknown
- 2010-04-16 GE GEAP201012423A patent/GEP20135938B/en unknown
- 2010-04-16 EP EP10714164.0A patent/EP2421534B1/en active Active
- 2010-04-16 DK DK10714164.0T patent/DK2421534T3/da active
- 2010-04-16 WO PCT/DK2010/050084 patent/WO2010121621A1/en active Application Filing
- 2010-04-23 AR ARP100101364A patent/AR076400A1/es not_active Application Discontinuation
-
2011
- 2011-09-25 IL IL215362A patent/IL215362A0/en active IP Right Grant
- 2011-10-07 TN TNP2011000504A patent/TN2011000504A1/en unknown
- 2011-10-19 CR CR20110554A patent/CR20110554A/es unknown
- 2011-10-20 DO DO2011000319A patent/DOP2011000319A/es unknown
- 2011-10-21 CL CL2011002631A patent/CL2011002631A1/es unknown
- 2011-10-21 ZA ZA2011/07731A patent/ZA201107731B/en unknown
- 2011-10-24 CO CO11143307A patent/CO6450649A2/es active IP Right Grant
-
2012
- 2012-07-27 DO DO2012000211A patent/DOP2012000211A/es unknown
-
2014
- 2014-09-15 HR HRP20140880AT patent/HRP20140880T1/hr unknown
- 2014-10-29 SM SM201400159T patent/SMT201400159B/xx unknown
- 2014-12-11 US US14/567,003 patent/US9475748B2/en active Active
-
2015
- 2015-07-29 HK HK15107256.7A patent/HK1206732A1/xx unknown
-
2016
- 2016-09-21 US US15/271,543 patent/US10034876B2/en active Active
-
2018
- 2018-06-27 US US16/020,799 patent/US10857149B2/en active Active
-
2021
- 2021-05-10 AR ARP210101276A patent/AR122051A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076400A1 (es) | Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente | |
| Ridolo et al. | Bilastine: new insight into antihistamine treatment | |
| ES2545959T3 (es) | Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer | |
| Werkhäuser et al. | Treatment of allergic rhinitis with ectoine containing nasal spray and eye drops in comparison with azelastine containing nasal spray and eye drops or with cromoglycic acid containing nasal spray | |
| HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BRPI0608205B8 (pt) | derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor | |
| CO6220962A2 (es) | Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| PE20060257A1 (es) | Composicion farmaceutica de flibanserina para el tratamiento de trastornos premestruales y otros trastornos sexuales femeninos | |
| BR112013031098A2 (pt) | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 | |
| AR084816A1 (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
| CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
| AR073755A1 (es) | Formulacion oral que comprende 4-[(1r,3s)-6-cloro-3-fenilindan-1-il]-1,2,2-trimetilpiperazina. uso. metodo. | |
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| UY30029A1 (es) | Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| ECSP10010567A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona | |
| BR112014009165A2 (pt) | sal e uso médico | |
| ECSP044979A (es) | Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| CO6280507A2 (es) | Nuevo uso medico de sales de propinato de 3-(2,2,2-trimetilhidrazinio) | |
| Wray | Essential dental therapeutics | |
| Buhl et al. | 1-Year Follow-Up Of COPD Patients After Withdrawal Of Inhaled Corticosteroid Maintenance Therapy: A Subgroup Analysis Of The DACCORD Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |